Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Poolbeg Pharma Plc | POLB | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.05 | 0.66% | 7.65 | 08:19:14 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 7.70 | 7.65 | 7.70 | 7.60 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 20/11/2024 07:09 by burtond1 Great news this for POLBhttps://www.lond |
Posted at 06/11/2024 09:20 by burtond1 https://www.londonst |
Posted at 06/11/2024 09:13 by pogue You do know the trail for POLB001 will be paid for by the pharmas who are wanting to use it? As for the oral tableting the cost of that has been budgeted for a long time and is miniscule. 50 subjects come in one day at a time pop a pill and come in next day to get a blood test to check the drug is in the bloodstream.Going to the NASDAQ has got the US fundraisers excited I expect as normally a listing there involves a fundraise however POLB is reversing into a SPAC so not going the normal route. |
Posted at 13/10/2024 08:54 by pogue Peterrr3I go to plenty events to window shop, going to an event does not mean there is a fundraise going to happen, I suggest you are taking one presentation out of context and extrapolating to the moon. I don’t see where they need the funds to be honest. They started out 3 years ago with around £20 million and now have around £10 million and are trailing POLB001 with 2 pharma companies’ drugs which suggests they are in advanced talks as if they goto human trial, they have done the In Vivo animal trial, there would have to be a contract signed setting out the partnership/selling deal should the result be positive as is normal in these situations in industry. No pharma company would want to increase the value of a 3rd party drug by proving it successful without having a price fixed beforehand. Why fundraise when you are that close to a massive monetisation of your lead asset? Why are they trying to find an orphan drug to sell? Well to make money perhaps? POLB have a pipeline of drugs they develop and sell/partner. Pentoxifylline has past phase II so they don’t need to put it through a trial. I don’t know what the deal will be with the owner but I cannot see POLB buying it unless they have a buyer. I suggest the most likely is a partnership where POLB help sell the drug and share in the profits. This is a capital light company they don’t spend money unless they have to bringing on drugs, have you seen the very small quantities of cash they have spent on the existing drugs in the pipeline? The fact they have spent only £10 million or so over 3 years is a clue. As I said I have listened to the Liam Trimble go on about POLB’s encapsulation tech being used in a trail later this year all 43 seconds off it and did not get excited about at the time as an oral encapsulation trial was being planned from the beginning of this year and was initially down to happen July/August so not seeing what the issue is, nothing new in it. The cost will be small and is being tested for use with another company’s drug they will contribute in some way same as those pharmas running the POLB001 trials did. The trial is very simple for encapsulation. Volunteer comes into medical establishment, pops a pill come backs next day to get a blood test to see if the drug has dispersed in their system, you really think they need a fundraise for this and it hasn’t been planned for? It is not the drug that’s being tested its oral encapsulation so not dangerous or expensive do you really think a sudden fundraise is needed for that as it has been planned for for a long time? As I said POLB does not have an obesity drug it’s the encapsulation that is being trailed. Should the trial work then there is a vast market out there for oral encapsulation way outside obesity drugs. Really cant see what you are going on about there. So to summarise why do you think they need a fundraise when they are getting close to a deal on POLB001? Oral encapsulation has been planned for trial for a long time and is not expensive to do. Pentoxifylline does not belong to POLB, they have an option on it and is past phase II so what cash do they need to spend as the option will more than likely be on a deal to sell in partnership with current owner and they dont need to conclude the deal if they see no buyers. |
Posted at 11/10/2024 13:00 by pogue peterrrthe NASDAQ move has been flagged in most presentations this year by JS as happening before year end. It was a casual remark in an intervierw last night with CF and about his life and had very little to do with POLB. Think you are projecting too much. Watch the video. Watch some presentations even. Edit he loaded up here, and many others did, not because of NASDAQ but quite simply the cancer drug pharmas need POLB001, again some watching presentations would help your undertanding. |
Posted at 18/9/2024 10:29 by sikhthetech "Poolbeg had a cash balance of £10.1 million as at 30 June 2024. The loss for the period amounted to £2.3 million (H1 23: £1.8 million) comprised of R&D expenses of £0.7 million (H1 23: £0.9 million), administrative expenses £2.1 million (H1 23: £1.4 million), and tax rebates and other income & charges of £0.6 million (H1 23: £0.5 million). "As expected, Cash & admin costs as predicted. My predictions £10m & £4m pa (cash & admin costs) compared to £10.1m & £4.2m reported. Revenue NIL. Increasing losses, increasing admin costs. I think they need a placing, as per my previous comments. The question is whether it will be a discounted placing and how deep that discount will be. sikhthetech - 29 Aug 2024 - 16:21:17 - 3529 of 3555 Poolbeg Pharma - POLB Pogue "They have more than enough cash for 2 years " Have they? Have you looked at the cash position and cash burn? I think there will be a placing by H1 2025. sikhthetech - 07 May 2024 - 12:14:12 - 3275 of 3439 Poolbeg Pharma - POLB Placing by H1 2025, ie by end of June next year. 3 years ago they raised £25m "Oversubscribed fundraise which resulted in an increased raise from £20m to £25m despite some investor scale back" Last week, they said they have £12.2m cash remaining, as of Dec 31st 2023. That balance figure is 4 months old. " Cash balance of £12.2 million as at 31 December 2023" Their admin costs have been increasing and with the new recruits, I think admin costs are now likely to be around £4m pa. Therefore, as of H1 end 2024, end of next month, I think they will have around £10m cash. They have had NIL revenue over the past 3 years. I, therefore, think they will need a placing by end of H1 next year. |
Posted at 18/9/2024 10:14 by pogue My typing was a bit rushed had a meeting to prep so my post should have read 'I assume you are not invested'.Anyway sugar coating are what CEOs are paid to do. If you want real info and are good at talking, I suggest going to an event and speaking to CEOs I do it regularly, am going to one tomorrow night, and you can get amazing information from how they answer a question if set correctly. Its an artform kind of like interrogation. Lots can be deduced from tone, body language and avoidance of points. In the case of POLB I see massive positives which I highlighted and these are in the short term. Highlighting minor negatives further down the pipeline is pointless as the company's share price will be decided on POLB001 and encapsulation in the short term and both are moving forward, I expect POLB001 to have the in human trials with cancer drugs soon and encapsulation should be up for sale/partnering in the New Year after human trials. If you are investing these are the points to focus on as those are what will give the share price a massive lift. If you are not invested then looking at the negatives and trying to spin them out as massive problems is what you do but you wont make money that way. |
Posted at 11/9/2024 21:04 by pogue They have brought two Pharma companies in which have brand new very effective cancer drugs. Problem with the drugs is that they cause cytokline storms so can only be used on limited amount of patients as they need to hospitalise those that take ill from the side effect thus are restricted by number of beds available. The pharmas have given POLB drugs to run trials with POLB001. You can work out the rest. |
Posted at 02/7/2024 11:38 by pogue peterr3I will spell it out as I feel you were listening to the wrong bits there. The lead asset of POLB is POLB001 and will be the first monetized. 2 pharmas are interested in it as their new very powerful cancer drugs have the side effect of cytokine storms. Cytokline storms mean that patients tie up hospital beds in cancer units thus reducing the amount of drugs that can be administered so huge incentive to find a drug that prevents them happening, like POLB001. Hugh incentive there for a phamra to partner with POLB if POLB001 works. Now as a stand alone drug POLB001 does the job all they have to do is prove it works whilst other drugs are in a patients system. The 2 pharmas have already given POLB the drugs, worth £millions, to run the trial and will pay for the trial as the market for their drug is 10s of $billions. We await the trial date how long do you think the pharmas are going to wait with a prize of that size? Now the other part you need to research is what normally happens in these situations ie a drug going to trial with another and what the trial contract normally says baring in mind that if it proves successful the value of POLB001 goes through the roof. Clue the contract has a section on that and I strongly suggest that is the reason for the delay as its a very important section.. Sorry if very direct but you have missed the point completely of what is happening and this board has so many halfwit derampers who avoid basic facts that I treat posters I dont know with suspicion. |
Posted at 07/2/2024 18:54 by troutisout We have all seen the great rise in HVO over the last 7 months, starting with contract wins in late June and July, then the positive trading update at the end of July and of course, what was the start of Institutional buying.Before that POLB mirrored HVO quite closely, deviating a little every now and then and then one or the other adjusting back. POLB showed the way in late Summer/Autumn 2022 with HVO mirroring the moves several weeks later. Then HVO leapt ahead of POLB in the late Summer/Autumn 2023, but the news of the Amryt team joining propelled POLB back up there again in November. As we went into the Christmas period and the New Year HVO has hit the rocket boosters with more contract wins and a really good TU. POLB has dithered and dropped slightly. I don't think the relationship between the two has broken (although the II buying in HVO will have diluted the relationship where many of the holders of HVO also held POLB). So we wait to see if POLB catches up again, it certainly looks a few weeks behind but the correlation has been strong up to now.... POLB black, HVO Blue, HVO overlaid on POLB from the first day of POLB trading free stock charts from uk.advfn.com |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
